[1]
|
Morice, P., Leary, A., Creutzberg, C. and Abu-Rustum, N.D.E. (2016) Endometrial Cancer. The Lancet, 387, 1094-1108.
https://doi.org/10.1016/S0140-6736(15)00130-0
|
[2]
|
Doherty, M.T., Sanni, O.B., Coleman, H.G., et al. (2020) Concurrent and Future Risk of Endometrial Cancer in Women with Endometrial Hyperplasia: A Systematic Review and Meta-Analysis. PLOS ONE, 15, e0232231.
https://doi.org/10.1371/journal.pone.0232231
|
[3]
|
Sanderson, P.A., Critchley, H.O.D., Williams, A.R.W., Arends, M.J. and Saunders, P.T.K. (2017) New Concepts for an Old Problem: The Diagnosis of Endometrial Hyperplasia. Human Reproduction Update, 23, 232-254.
https://doi.org/10.1093/humupd/dmw042
|
[4]
|
World Health Organization (2020) WHO Classification of Tumours. 5th Edition, Volume 4: Female Genital Tumours. WHO, Geneva.
|
[5]
|
Kurman, R., Careangiu, M., Herrington, C., et al. (2014) World Health Organisation Classification of Tumors of Female Reproductive Organs. 4th Edition, International Agency for Research on Cancer (LARC) Press, Lyon.
|
[6]
|
全国卫生产业企业管理协会妇幼健康产业分会生殖内分泌学组. 中国子宫内膜增生诊疗共识[J]. 生殖医学杂志, 2017, 26(10): 957-960.
|
[7]
|
Committee on Gynecologic Practice Society of Gynecologic Oncology (2015) Committee Opinion No. 631 Endometrial Intraepithelial Neoplasia. Obstetrics & Gynecology, 125, 1272-1278.
https://doi.org/10.1097/01.AOG.0000465189.50026.20
|
[8]
|
Ordi, J., Bergeron, C., Hardisson, D., McCluggage, W.G., Hollema, H., Felix, A., et al. (2014) Reproducibility of Current Classifications of Endometrial Endometrioid Glandular Proliferations: Further Evidence Supporting a Simplified Classification. Histopathology, 64, 284-292. https://doi.org/10.1111/his.12249
|
[9]
|
Zeleniuch-Jacquotte, A., Akhmedkhanov, A., Kato, I., Koenig, K.L., Shore, R.E., Kim, M.Y., Levitz, M., Mittal, K.R., Raju, U., Banerjee, S, et al. (2001) Postmenopausal Endogenous Oestrogens and Risk of Endometrial Cancer: Results of A Prospective Study. British Journal of Cancer, 84, 975-981. https://doi.org/10.1054/bjoc.2001.1704
|
[10]
|
Nees, L.K., Heublein, S., Steinmacher, S., Juhasz-Böss, I., Brucker, S., Tempfer, C.B. and Wallwiener, M. (2022) Endometrial Hyperplasia as a Risk Factor of Endometrial Cancer. Archives of Gynecology and Obstetrics, 306, 407-421.
https://doi.org/10.1007/s00404-021-06380-5
|
[11]
|
Wise, M.R., Gill, P., Lensen, S., Thompson, J.M. and Farquhar, C.M. (2016) Body Mass Index Trumps Age in Decision for Endometrial Biopsy: Cohort Study of Symptomatic Premenopausal Women. American Journal of Obstetrics and Gynecology, 215, 598E591-598E598. https://doi.org/10.1016/j.ajog.2016.06.006
|
[12]
|
Ring, K.L., Mills, A.M. and Modesitt, S.C. (2022) Endometrial Hyperplasia. Obstetrics & Gynecology, 140, 1061-1075.
https://doi.org/10.1097/AOG.0000000000004989
|
[13]
|
Dumesic, D.A. and Lobo, R.A. (2013) Cancer Risk and PCOS. Steroids, 78, 782-785.
https://doi.org/10.1016/j.steroids.2013.04.004
|
[14]
|
Shan, W., Ning, C., Luo, X., Zhou, Q., Gu, C., Zhang, Z., et al. (2014) Hyperinsulinemia Is Associated with Endometrial Hyperplasia and Disordered Proliferative Endometrium: A Prospective Cross-Sectional Study. Gynecologic Oncology, 132, 606-610. https://doi.org/10.1016/j.ygyno.2014.01.004
|
[15]
|
Campagnoli, C., Abba, C., Ambroggio, S., Brucato, T. and Pasanisi, P. (2013) Life-Style and Metformin for the Prevention of Endometrial Pathology in Postmenopausal Women. Gynecological Endocrinology, 29, 119-124.
https://doi.org/10.3109/09513590.2012.706671
|
[16]
|
Bergman, L., Beelen, M.L., Gallee, M.P., Hollema, H., Benraadt, J. and Van Leeuwen, F.E. (2000) Risk and Prognosis of Endometrial Cancer after Tamoxifen for Breast Cancer. The Lancet (London, England), 356, 881-887.
https://doi.org/10.1016/S0140-6736(00)02677-5
|
[17]
|
Lancaster, J.M., Powell, C.B., Chen, L.M. and Richardson, D.L. (2015) Committee SGOCP: Society of Gynecologic Oncology Statement on Risk Assessment for Inherited Gyne-cologic Cancer Predispositions. Gynecologic Oncology, 136, 3-7. https://doi.org/10.1016/j.ygyno.2014.09.009
|
[18]
|
Ryan, N.A.J., McMahon, R., Tobi, S., Snowsill, T., Esquibel, S., Wallace, A.J., Bunstone, S., Bowers, N., Mosneag, I.E., Kitson, S.J., et al. (2020) The Proportion of Endometrial Tu-mours Associated with Lynch Syndrome (PETALS): A Prospective Cross-Sectional Study. PLOS Medicine, 17, e1003263. https://doi.org/10.1371/journal.pmed.1003263
|
[19]
|
Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M.R., et al. (2016) ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-Up. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 27, 16-41.
|
[20]
|
Manchanda, R., Saridogan, E., Abdelraheim, A., Johnson, M., Rosenthal, A.N., Benjamin, E., Brunell, C., Side, L., Gessler, S., Jacobs, I., et al. (2012) Annual Outpatient Hysteroscopy and Endometrial Sampling (OHES) in HNPCC/ Lynch Syndrome (LS). Archives of Gynecology and Obstetrics, 286, 1555-1562.
https://doi.org/10.1007/s00404-012-2492-2
|
[21]
|
Auclair, M.H., Yong, P.J., Salvador, S., Thurston, J., Colgan, T.T.J. and Sebastianelli, A. (2019) Guideline No. 390- Classification and Management of Endometrial Hyperplasia. Journal of Obstetrics and Gynaecology Canada, 41, 1789- 1800. https://doi.org/10.1016/j.jogc.2019.03.025
|
[22]
|
Moore, E. and Shafi, M. (2013) Endometrial Hyperplasia. Ob-stetrics, Gynaecology and Reproductive Medicine, 23, 88-93. https://doi.org/10.1016/j.ogrm.2013.01.002
|
[23]
|
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M.R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) ESGO/ESTRO/ESP Guidelines for the Management of Patients with 25 Endometrial Carcinoma. International Journal of Gynecological Cancer, 31, 12-39. https://doi.org/10.1136/ijgc-2020-002230
|
[24]
|
Uccella, S., Zorzato, P.C., Dababou, S., Bosco, M., Torella, M., Braga, A., Frigerio, M., Gardella, B., Cianci, S., Laganà, A.S., Franchi, M.P. and Garzon, S. (2022) Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women. Medicina (Kaunas), 58, Article No. 1256.
https://doi.org/10.3390/medicina58091256
|
[25]
|
Obermair, A., Baxter, E., Brennan, D.J., McAlpine, J.N., Muellerer, J.J., Amant, F., Van Gent, M.D.J.M., Coleman, R.L., Westin, S.N., Yates, M.S., et al. (2020) Fertility-Sparing Treatment in Early Endometrial Cancer: Current State and Future Strategies. Obstetrics & Gynecology Science, 63, 417-431. https://doi.org/10.5468/ogs.19169
|
[26]
|
Stewart, K., Campbell, S., Frumovitz, M., Ramirez, P.T. and McKenzie, L.J. (2021) Fertility Considerations Prior to Conservative Management of Gynecologic Cancers. International Journal of Gynecological Cancer, 31, 339-344.
https://doi.org/10.1136/ijgc-2020-001783
|
[27]
|
Moradan, S., Nikkhah, N. and Mirmohammadkhanai, M. (2017) Comparing the Administration of Letrozole and Megestrol Acetate in the Treatment of Women with Simple Endometrial Hyperplasia without Atypia: A Randomized Clinical Trial. Advances in Therapy, 34, 1211-1220. https://doi.org/10.1007/s12325-017-0509-8
|
[28]
|
Park, J.Y., Lee, S.H., Seong, S.J., et al. (2013) Progestin Re-Treatment in Patients with Recurrent Endometrial Adenocarcinoma after Successful Fertility-Sparing Management Using Progestin. Gynecologic Oncology, 129, 7-11.
https://doi.org/10.1016/j.ygyno.2012.12.037
|
[29]
|
Contreras, N.A., Sabadell, J., Verdaguer, P., Julià, C. and Fernández-Montolí, M.E. (2022) Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions. International Journal of Molecular Sciences, 23, Article No. 2531. https://doi.org/10.3390/ijms23052531
|